<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704143</url>
  </required_header>
  <id_info>
    <org_study_id>Changhai Hosp</org_study_id>
    <nct_id>NCT02704143</nct_id>
  </id_info>
  <brief_title>Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of combination of SBRT with sequential S-1 in treating patients with
      locally advanced pancreatic cancer and poor medical conditions will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the incidence rate of pancreatic cancer is not as high as that of other
      gastrointestinal carcinoma in China, the cancer mortalities of males and females ranked the
      sixth and seventh respectively in 2013, with a surprising low 5-year survival rate (&lt;5%).
      Only 15%-20% patients are suitable for surgeries among those first diagnosed with pancreatic
      cancer and the 5-year survival rate of patients with R0 resection is still less than 20%.

      Therefore, better efficacy is not available via surgeries alone resulting in great emphasis
      on adjuvant chemoradiotherapy. In 1997, gemcitabine was confirmed to be the standard
      chemotherapy for pancreatic cancer. However, it has not been proved that gemcitabine
      significantly improved prognosis in long term follow-up while some patients are refractory to
      gemcitabine. Hence, development of more effective chemotherapy is urgent.

      S-1 is the prodrug of 5-fluorouracil (5-FU), comprised of tegafur, gimeracil
      (dihydropyrimidine dehydrogenase inhibitor) and oteracil (the inhibitor of phosphorylation in
      gastrointestinal tract) with a ratio of 1:0.4:1. The first phase II clinical trials showed
      good clinical efficacy with S-1.Moreover, Ueno et al. identified better objective response
      rates with S-1 than those with gemcitabine. Besides, S-1 is not inferior to gemcitabine
      regarding to overall survival rates and progression free survival rates. And significant
      improvement of progression free survival rates can be achieved by combination of S-1 and
      gemcitabine. There was no difference between incidence rates of adverse effects of S-1 and
      gemcitabine, with more gastrointestinal toxicities with S-1 while more hematologic toxicities
      with gemcitabine. Therefore, S-1 is an alternative for treating locally advanced or
      metastatic pancreatic cancer, especially for those resistant to gemcitabine. Although there
      are no phase III studies on S-1, phase II studies have already shown better disease control
      rates (52%-58%), median overall survival time (4.5-6.3 months) and tolerable adverse effects
      in advanced pancreatic cancer resistant to gemcitabine treated with S-1.

      Though S-1 is appropriate for advanced pancreatic cancer, it is not superior to gemcitabine
      with respect to clinical efficacy. In addition, fewer encouraging results are gained with
      combination of S-1 and other drug. As a result, S-1 combined with radiotherapy is gradually
      applied in treatment of pancreatic cancer.

      5-FU was proved to be radiosensitive thus improving clinical efficacy. S-1 combined with
      radiotherapy has demonstrated better prognosis with the median overall survival time of
      12.9-16.8 months. Furthermore, some patients can be operable after S-1 and radiotherapy.

      Compared with conventional radiation, a single-fraction dose and total dose of target volume
      can be increased in stereotactic body radiation therapy (SBRT). In addition, doses of organs
      at risk would be reduced, thus effectively improving local control rates and reducing
      radiation related toxicity. Shorter courses of SBRT also enhance patients' compliance and
      render the initial of other treatment on schedule possible. Nevertheless, there are few
      studies focusing on S-1 combined with SBRT for locally advanced pancreatic cancer. Especially
      for patients with poor medical coonditions, though gemcitabine alone is recommended in the
      NCCN guideline, S-1 may be a better option due to more adverse effects induced by gemcitabine
      in Asian. Additionally, local ablative treatment combined with chemotherapy may provide more
      survival benefits for those patients. Hence, efficacy of combination of S-1 and SBRT needs to
      be further confirmed. Based on our experience in treating locally advanced pancreatic cancer,
      SBRT combined with sequential S-1 as the initial treatment for patients with locally advanced
      pancreatic cancer and poor medical conditions is proposed to evaluate its clinical efficacy.

      Study Procedure:

        1. CyberKnife SBRT body fixation (vacuum-bag) will be used in immobilizing the body, the
           arms and the legs. Patients will undergo a plain CT as well as an enhanced pancreatic
           parenchymal CT for radiation treatment planning and target delineation.

        2. SBRT will be delivered on CyberKnife with Synchrony Respiratory Tracking system. The
           tumor will be tracked with implanted fiducial markers by Fiducial Tracking System.
           Treatment will be delivered in 5 fractions within 1 to 2 weeks at the discretion of the
           investigator.

        3. A body fixation (vacuum-bag) will be used in immobilizing the body, the arms (both arms
           are along the body) and the legs.

        4. The total doses depend on patients' medical conditions, ranging from 35Gy-40Gy/5Fx.

        5. Patients receive 80 mg of S-1 per square meter of body surface area twice a day for 4
           weeks, followed by 2 weeks of rest as one course, which would repeat for six cycles.The
           initiation of S-1 is one month after SBRT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>stereotactic bodt radiation therapy plus sequential S-1 for locally pancreatic cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year Overall Survival Rate</measure>
    <time_frame>1 year</time_frame>
    <description>One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Toxicities Following SBRT</measure>
    <time_frame>Within 90 days after completion of SBRT</time_frame>
    <description>The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Late Toxicities Following SBRT</measure>
    <time_frame>90 days after SBRT</time_frame>
    <description>The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Median Progression Free Survival Time Will be Determined.</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of Life Will be Analyzed.</measure>
    <time_frame>1 years</time_frame>
    <description>The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival Will be Determined.</measure>
    <time_frame>3 years</time_frame>
    <description>Median overall survival is calculated by Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Combination of Cyberknife with S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>combination of Cyberknife with S-1</intervention_name>
    <description>Radiation therapy combined with chemotherapy</description>
    <arm_group_label>Combination of Cyberknife with S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Locally advanced pancreatic cancer proved by CT or MRI and biopsy

          2. Without any other treatment before SBRT

          3. A life expectancy of &gt;3months

          4. ECOG: 2 or 3 points

          5. Age of 18-75 years old

          6. Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.5 ×10^9 cells/L,
             leukocyte count≥ 3.5 ×10^9 cells/L, platelets ≥ 70×10^9 cells/L, hemoglobin ≥ 8.0 g/dl

          7. Liver and kidney function tests: Albumin &gt; 2.5 g/dL, total bilirubin &lt; 3 mg/dL,
             creatinine &lt; 2.0 mg/dL, AST&lt;2.5 × ULN(Upper Limit of Normal)(0-64U/L), ALT&lt;2.5 ×
             ULN(0-64U/L)

          8. INR &lt; 2 (0.9-1.1)

          9. Ability of the research subject or authorized legal representative to understand and
             the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Prior surgery, chemotherapy or radiation for the pancreatic cancer

          2. Evidences of metastatic disease such as nodal or distant metastases by abdomen CT and
             chest CT or FDG PET-CT

          3. Contraindication to receiving radiotherapy

          4. ECOG: 0-1 point

          5. Age&lt;18 or &gt;75

          6. Abnormal results of blood routine examinations and liver and kidney tests

          7. Patients with active inflammatory bowel diseases or peptic ulcer

          8. Gastrointestinal bleeding or perforation within 6 months

          9. Heart failure: NYHA III-IV

         10. Women who are pregnant

         11. Participation in another clinical treatment trial while on study

         12. Patients in whom fiducial implantation was not possible

         13. Inability of the research subject or authorized legal representative to understand and
             the willingness to sign a written informed consent document.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huo Jun Zhang, MD., PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.</citation>
    <PMID>22237781</PMID>
  </reference>
  <reference>
    <citation>Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999 Jul;189(1):1-7.</citation>
    <PMID>10401733</PMID>
  </reference>
  <reference>
    <citation>Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003 Mar;27(3):324-9. Epub 2003 Feb 27.</citation>
    <PMID>12607060</PMID>
  </reference>
  <reference>
    <citation>Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50.</citation>
    <PMID>15585381</PMID>
  </reference>
  <reference>
    <citation>Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005 Jul;76(1):48-53.</citation>
    <PMID>15990186</PMID>
  </reference>
  <reference>
    <citation>Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13.</citation>
    <PMID>9196156</PMID>
  </reference>
  <reference>
    <citation>Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68(2-3):171-8. Epub 2005 Jul 4.</citation>
    <PMID>16006754</PMID>
  </reference>
  <reference>
    <citation>Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1.</citation>
    <PMID>23547081</PMID>
  </reference>
  <reference>
    <citation>Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9. doi: 10.1007/s00280-008-0741-7. Epub 2008 Apr 9.</citation>
    <PMID>18398614</PMID>
  </reference>
  <reference>
    <citation>Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011 Feb;67(2):249-54. doi: 10.1007/s00280-010-1311-3. Epub 2010 Mar 30.</citation>
    <PMID>20352216</PMID>
  </reference>
  <reference>
    <citation>Mizuno N, Yamao K, Komatsu Y, et al. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabinerefractory pancreatic cancer. J Clin Oncol, 2012, 30 (suppl 34): abstr 263</citation>
  </reference>
  <reference>
    <citation>Okusaka T, Ohkawa S, Isayama H, et al. Randomized phase II trial of S-1 versus S-1 plus oxaliplatin (SOX) in patients with GEM refractory pancreatic cancer. ESMO, 2012, abstract 1437</citation>
  </reference>
  <reference>
    <citation>Ge F, Xu N, Bai Y, Ba Y, Zhang Y, Li F, Xu H, Jia R, Wang Y, Lin L, Xu J. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist. 2014 Nov;19(11):1133-4. doi: 10.1634/theoncologist.2014-0223. Epub 2014 Oct 1.</citation>
    <PMID>25273077</PMID>
  </reference>
  <reference>
    <citation>Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004 Jun 1;22(11):2214-32. Review.</citation>
    <PMID>15169811</PMID>
  </reference>
  <reference>
    <citation>Moningi S, Marciscano AE, Rosati LM, Ng SK, Teboh Forbang R, Jackson J, Chang DT, Koong AC, Herman JM. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther. 2014 Dec;14(12):1461-75. doi: 10.1586/14737140.2014.952286. Epub 2014 Sep 3. Review.</citation>
    <PMID>25183386</PMID>
  </reference>
  <reference>
    <citation>Berber B, Sanabria JR, Braun K, Yao M, Ellis RJ, Kunos CA, Sohn J, Machtay M, Teh BS, Huang Z, Mayr NA, Lo SS. Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2013 Apr;13(4):481-7. doi: 10.1586/era.13.19. Review.</citation>
    <PMID>23560842</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <results_first_submitted>May 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2020</results_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Huo Jun</investigator_full_name>
    <investigator_title>Director of Radiation Oncology Department</investigator_title>
  </responsible_party>
  <keyword>stereotactic body radiation therapy</keyword>
  <keyword>S-1</keyword>
  <keyword>locally advanced pancreatic cancer</keyword>
  <keyword>poor medical conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02704143/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from February 2016 to March 2018 in Changhai Hospital affiliated to Navy Medical University.</recruitment_details>
      <pre_assignment_details>There were significant events that occur after participant enrollment, but prior to assignment of participants to an arm or group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination of Cyberknife With S-1</title>
          <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients were enrolled according to the inclusion and exclusion criteria. All patients received follow-ups and were included in the final analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Combination of Cyberknife With S-1</title>
          <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with sequential S-1: Radiation therapy combined with sequential chemotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" lower_limit="63.5" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>One-year Overall Survival Rate</title>
        <description>One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Cyberknife With S-1</title>
            <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Overall Survival Rate</title>
          <description>One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Toxicities Following SBRT</title>
        <description>The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria.</description>
        <time_frame>Within 90 days after completion of SBRT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Cyberknife With S-1</title>
            <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Toxicities Following SBRT</title>
          <description>The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Late Toxicities Following SBRT</title>
        <description>The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria.</description>
        <time_frame>90 days after SBRT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Cyberknife With S-1</title>
            <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Toxicities Following SBRT</title>
          <description>The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Median Progression Free Survival Time Will be Determined.</title>
        <description>Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Cyberknife With S-1</title>
            <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Progression Free Survival Time Will be Determined.</title>
          <description>Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.1" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Quality of Life Will be Analyzed.</title>
        <description>The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively).</description>
        <time_frame>1 years</time_frame>
        <population>All domains of QLQ-C30 at 6 months after treatment are reported. Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all following domains is 0-100 (the minimum and maximum score is 0 and 100 points, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Combination of Cyberknife With S-1</title>
            <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Quality of Life Will be Analyzed.</title>
          <description>The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively).</description>
          <population>All domains of QLQ-C30 at 6 months after treatment are reported. Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all following domains is 0-100 (the minimum and maximum score is 0 and 100 points, respectively).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global health status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="33.3" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="46.7" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="16.7" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="41.7" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="33.3" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="33.3" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="33.3" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="33.3" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" lower_limit="33.3" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="0" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="33.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" lower_limit="0" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival Will be Determined.</title>
        <description>Median overall survival is calculated by Kaplan-Meier method.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Cyberknife With S-1</title>
            <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Will be Determined.</title>
          <description>Median overall survival is calculated by Kaplan-Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="11.9" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Radiation-induced acute toxicities are adverse effects that occur within 90 days after treatment, and determined by the Radiation Therapy Oncology Group, &quot;Acute radiation morbidity scoring criteria&quot;. Late toxicities occurring three months after SBRT are evaluated by the Radiation Therapy Oncology Group/European Organization for Research on the Treatment of Cancer, &quot;Late radiation morbidity scoring schema&quot;.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination of Cyberknife With S-1</title>
          <description>Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
combination of Cyberknife with S-1: Radiation therapy combined with chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomitting</sub_title>
                <description>Radiation-induced acute toxicities are adverse effects that occur within 90 days after treatment, and determined by the Radiation Therapy Oncology Group, &quot;Acute radiation morbidity scoring criteria&quot;.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lacks of comparison of gemcitabine alone or palliative radiotherapy recommended in NCCN guideline.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Huojun Zhang</name_or_title>
      <organization>Changhai Hospital affiliated to Navy Medical University</organization>
      <phone>86-021-31162207</phone>
      <email>chyyzhj@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

